Navigation Links
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
Date:10/1/2008

LA JOLLA, Calif., Oct. 1 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it held a successful End-of-Phase II meeting for tezampanel with the U.S. Food and Drug Administration (FDA) on September 29, 2008. Based on a review of the Phase II data, the FDA agreed that TorreyPines may initiate a Phase III program for tezampanel in acute migraine. The FDA also confirmed that the required thorough QT/QTc study for tezampanel can be conducted in parallel with the first Phase III pivotal trial. The timing for initiation of a Phase III trial is dependent on the company securing a development partner or funding for the program.

The FDA meeting follows the successful completion of a 306-patient, Phase IIb acute migraine trial that demonstrated a single 40 mg dose of tezampanel was safe, well-tolerated and effective in relieving headache pain at two hours post-dose. The Phase III clinical trial design for tezampanel will evaluate the 40 mg dose as well as a lower dose, consistent with the FDA recommendation that the lowest effective dose should be identified in the development of investigational drugs.

"We are pleased with the outcome of our meeting with the FDA and their go-ahead for a Phase III program," said Ev Graham, acting chief executive officer of TorreyPines. "This successful milestone, the first in a series of clinical milestones we expect to meet this year, should significantly help us achieve our strategy of securing a corporate partner or other funding to continue development of tezampanel. We are also on track to report by the end of the year, data from our ongoing Phase I study of NGX426, the oral prodrug of tezampanel, in a capsaicin model of hyperalgesia, as well as a Phase II study of
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Verenium Corporation (Nasdaq: VRNM ), ... and commercialization of high-performance enzymes, today announced that ... present at two upcoming conferences. (Logo: ... the Second Annual Marcum LLP Microcap Conference on Thursday, ... New York City.  The presentation is scheduled to begin ...
(Date:5/23/2013)... South Korea , May 23, 2013 /PRNewswire/ ... with SillaJen, Inc., a private biotherapeutics and contract ... targeted biological products for cancer, announced today a ... in patients treated with the oncolytic and immunotherapeutic ... This research was published in the May ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 ... ancestry tracing for people of African descent, today ... product offering. For people of all races, myDNAmix ... from five distinct populations: Indigenous Americas (Native American), ... India Subcontinent. , Originally launched in ...
(Date:5/23/2013)... Bed bugs compromised Penn State. ... confirmed it. Meanwhile, My Cleaning Products offered complimentary samples of ... the pests without using harmful chemical elements. , Based ... the affected building was actually a dormitory , My ... made on May 13 and bed bug presence was confirmed ...
Breaking Biology Technology:Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... Emphasis on Drug Development and Recent ... Private Equity ... (Nasdaq: LXRX ) announced several changes to the,composition of ... and the completion of a major strategic financing,with Invus, LP. ...
... Sept. 25 NanoBio(R) Corporation, a,biopharmaceutical company developing ... prevent serious infections, today announced,the addition of four ... Lyou-fu Ma, PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert ... NanoBio in developing and commercializing,its novel topical anti-infectives ...
... SeqWright, Inc., an international,leader in the field ... Applied Biosystems (ABI) to purchase ABI,s next generation,SOLiD(TM) ... to offer commercial access to the latest in ... between,SeqWright and ABI that grows stronger with time. ...
Cached Biology Technology:Lexicon Appoints Judith Swain, M.D. to Board of Directors 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 3Lexicon Appoints Judith Swain, M.D. to Board of Directors 4NanoBio Expands Drug Development Team for Its Anti-Infective Products 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 3SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System 2
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... 160 participants gathered this week for the seventh ... year,s topic, "Synthetic Biology," brought together scientists, engineers, ... and social issues surrounding the emerging field of ... molecular biology at Princeton University and this year,s ...
... 2009 -- A USDOE and USDA study concluded that ... cropland pasture could be converted from current uses to ... which biomass could be harvested for use as a ... monoculture from which substantial quantities of biomass are removed ...
... string of recent discoveries about the multiple health benefits of ... awareness of the huge numbers of people who are deficient ... of it as "nature,s antibiotic." On issues ranging from ... disease and even vulnerability to influenza, vitamin D is now ...
Cached Biology News:Synthetic biology offers new opportunities for interdisciplinary collaboration 2Switchgrass produces biomass efficiently 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
... PGE1-d4 contains 4 deuterium atoms at the ... is intended for use as an internal ... GC- or LC-mass spectrometry. PGE1 is the ... but it is virtually undetectable in the ...
Biology Products: